DK1838301T3 - Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til behandling af smerter - Google Patents
Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til behandling af smerter Download PDFInfo
- Publication number
- DK1838301T3 DK1838301T3 DK04802396.4T DK04802396T DK1838301T3 DK 1838301 T3 DK1838301 T3 DK 1838301T3 DK 04802396 T DK04802396 T DK 04802396T DK 1838301 T3 DK1838301 T3 DK 1838301T3
- Authority
- DK
- Denmark
- Prior art keywords
- pain
- injection
- treatment
- agent
- local
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 69
- 230000036407 pain Effects 0.000 title claims description 65
- 239000003795 chemical substances by application Substances 0.000 title claims description 60
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003053 toxin Substances 0.000 title claims 6
- 231100000765 toxin Toxicity 0.000 title claims 6
- 239000007924 injection Substances 0.000 claims description 72
- 238000002347 injection Methods 0.000 claims description 72
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims description 69
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims description 57
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims description 57
- 229940073454 resiniferatoxin Drugs 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 35
- 210000000988 bone and bone Anatomy 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 24
- 208000006820 Arthralgia Diseases 0.000 claims description 22
- 206010006002 Bone pain Diseases 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 230000005499 meniscus Effects 0.000 claims description 20
- 206010034464 Periarthritis Diseases 0.000 claims description 18
- 206010058029 Arthrofibrosis Diseases 0.000 claims description 16
- 206010028851 Necrosis Diseases 0.000 claims description 16
- 239000003589 local anesthetic agent Substances 0.000 claims description 16
- 230000017074 necrotic cell death Effects 0.000 claims description 16
- 208000000112 Myalgia Diseases 0.000 claims description 14
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 14
- 201000010603 frozen shoulder Diseases 0.000 claims description 14
- 208000007538 neurilemmoma Diseases 0.000 claims description 14
- 206010039667 schwannoma Diseases 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 210000005036 nerve Anatomy 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000007850 degeneration Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 206010072970 Meniscus injury Diseases 0.000 claims description 9
- 210000003281 pleural cavity Anatomy 0.000 claims description 9
- 208000008035 Back Pain Diseases 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 8
- 206010061159 Foot deformity Diseases 0.000 claims description 8
- 208000001963 Hallux Valgus Diseases 0.000 claims description 8
- 201000009859 Osteochondrosis Diseases 0.000 claims description 8
- 208000004983 Phantom Limb Diseases 0.000 claims description 8
- 206010056238 Phantom pain Diseases 0.000 claims description 8
- 206010035623 Pleuritic pain Diseases 0.000 claims description 8
- 229910001424 calcium ion Inorganic materials 0.000 claims description 8
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 8
- 208000002925 dental caries Diseases 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000010255 intramuscular injection Methods 0.000 claims description 8
- 239000007927 intramuscular injection Substances 0.000 claims description 8
- 238000007443 liposuction Methods 0.000 claims description 8
- 208000013465 muscle pain Diseases 0.000 claims description 8
- 230000002981 neuropathic effect Effects 0.000 claims description 8
- 230000001148 spastic effect Effects 0.000 claims description 8
- 201000004595 synovitis Diseases 0.000 claims description 8
- 206010002153 Anal fissure Diseases 0.000 claims description 7
- 208000016583 Anus disease Diseases 0.000 claims description 7
- 206010007710 Cartilage injury Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 208000009531 Fissure in Ano Diseases 0.000 claims description 7
- 206010009887 colitis Diseases 0.000 claims description 7
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000001223 septic arthritis Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 206010023230 Joint stiffness Diseases 0.000 claims description 5
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 5
- 206010053692 Wound complication Diseases 0.000 claims description 5
- 238000002674 endoscopic surgery Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 229910052788 barium Inorganic materials 0.000 claims description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 230000003040 nociceptive effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 230000002638 denervation Effects 0.000 claims description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004126 nerve fiber Anatomy 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008354 sodium chloride injection Substances 0.000 claims description 2
- 239000008223 sterile water Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 208000002472 Morton Neuroma Diseases 0.000 claims 5
- 208000005890 Neuroma Diseases 0.000 claims 5
- 159000000007 calcium salts Chemical class 0.000 claims 5
- 239000004053 dental implant Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000012530 fluid Substances 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 5
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 4
- 208000015001 muscle soreness Diseases 0.000 claims 4
- 230000003239 periodontal effect Effects 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 230000009172 bursting Effects 0.000 claims 2
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- WWVBRUMYFUDEJQ-UHFFFAOYSA-N 1-ethoxyethane-1,2-diol Chemical compound CCOC(O)CO WWVBRUMYFUDEJQ-UHFFFAOYSA-N 0.000 claims 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 claims 1
- IWRUDYQZPTVTPA-UHFFFAOYSA-N Iophendylate Chemical compound CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I IWRUDYQZPTVTPA-UHFFFAOYSA-N 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 108010012215 Ornipressin Proteins 0.000 claims 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229940029393 iophendylate Drugs 0.000 claims 1
- MUNMIGOEDGHVLE-LGYYRGKSSA-N ornipressin Chemical compound NC(=O)CNC(=O)[C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 MUNMIGOEDGHVLE-LGYYRGKSSA-N 0.000 claims 1
- 229960004571 ornipressin Drugs 0.000 claims 1
- 201000006727 periodontosis Diseases 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 210000003741 urothelium Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 9
- 235000017663 capsaicin Nutrition 0.000 description 9
- 210000001503 joint Anatomy 0.000 description 9
- 210000000281 joint capsule Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 229960005015 local anesthetics Drugs 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 6
- 208000004371 toothache Diseases 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 5
- 230000002887 neurotoxic effect Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 229960002504 capsaicin Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 201000001245 periodontitis Diseases 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 210000000323 shoulder joint Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 241001260012 Bursa Species 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- -1 ethoxyethylene diglycol Chemical compound 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008349 purified phosphatidyl choline Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 239000000105 vanilloid receptor agonist Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (26)
1. Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til behandling af smerter ved artrose artritis, især reumatoid artritis og infektiøs artritis chondrocalcinose ligamentære skader menisklæsion bruskskader synovitis artrofibrose Morbus Sudeck nekrose i leddelene neuropatiske ledsmerter; behandling af knoglesmerter efter knogleoperation ved påføring på knoglen, f.eks. efter bækkenkamosteotomi hallux valgus korrektion; behandling af knoglesmerter ved injektion i knoglen f.eks. ved femurhovednekrose i femurhovedet i hvirvellegemet ved osteochondrose behandling af smerter ved ledstivhed, især artrofibrose frossen skulder; behandling af muskelsmerter ved intramuskulær injektion, f.eks. ved fibersprængning muskelømhed spastiske lidelser; injektion i den smertende menisk ved meniskdegeneration eller meniskbristning, behandling af rygsmerter ved injektion i båndskiven ved båndskivedegeneration eller båndskivebristning; injektion omkring en smertende nerve, f.eks. ved trigeminusneuralgi neurinom Mortons neurom fantomsmerte cicatricielt neurom; behandling af tandsmerter intra/peridentalt ved: karies alle former for tandsmerte inden/ved/efter tandudtrækning inden/ved/efter tandimplantat anvendelse ved parodontose anvendelse ved blotlagte tandhalse; injektion i pleurahulen ved pleuritiske smerter; instillation i tarmen ved tarmsmerter, især Colitis ulcerosa, Crohns sygdom, analfissur, hæmorider; ledsmerter; knoglesmerter efter osteotomie; smerter ved frossen skulder; smerter ved tendonitis; smerter ved myalgi; smerter ved bløddelstumorer knoglesmerter eller knogleledssmerter, kendetegnet ved, at A) midlet yderligere indeholder et calciumsalt; B) calciumionkoncentrationen er større end 2 mMol; C) midlet er opløst i en pufferopløsning med en pH-værdi højere end 7,6, fortrinsvis højere end 8,5; og D) midlet ikke indeholder et lokalanæstetikum.
2. Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til behandling af a) lokale sårsmerter efter OP i form af en skyllevæske til intraoperativ anvendelse ved en åben eller artroskopisk eller endoskopisk operation eller liposuction; b) lokal behandling af ledsmerter ved intraartikulær injektion ved chondrocalcinose ligamentære skader menisklæsion bruskskader synovitis artrofibrose Morbus Sudeck nekrose i leddelene neuropatiske ledsmerter c) lokal behandling af knoglesmerter efter knogleoperation ved påføring på knoglen, f.eks. efter bækkenkamosteotomi hallux valgus korrektion; d) behandling af knoglesmerter ved injektion i knoglen, især ved femurhovednekrose i femurhovedet, i hvirvellegemet ved osteochrondrose; e) lokal behandling af smerter ved ledstivhed, især ved artrofibrose eller frossen skulder; f) lokal behandling af muskelsmerter ved intramuskulær injektion, især ved fibersprængning, muskelømhed eller spastiske lidelser; g) lokal injektion i den smertende menisk ved meniskdegeneration eller meniskbristning; h) behandling af rygsmerter ved injektion i båndskiven ved båndskivedegeneration eller båndskivebristning; i) injektion omkring en smertende nerve, især ved trigeminusneuralgi, neurinom, Mortons neurom, fantomsmerte, cicatricielt neurom; j) behandling af tandsmerter ved lokal anvendelse intra/peridentalt, især ved karies, alle former for tandsmerte, inden/ved/efter tandudtrækning, inden/ved/efter tandimplantat, lokal anvendelse ved parodontose, lokal anvendelse ved blotlagte tandhalse; k) injektion i pleurahulen ved pleuritiske smerter; l) instillation i tarmen ved tarmsmerter, især ved Colitis ulcerosa, Crohns sygdom, analfissur; kendetegnet ved, at A) midlet yderligere indeholder et calciumsalt; B) calciumionkoncentrationen er større end 2 mMol; C) midlet er opløst i en pufferopløsning med en pH-værdi højere end 7,6, fortrinsvis højere end 8,5; D) der anvendes ikke andre farmakologisk virksomme stoffer; og E) midlet indeholder en permeationsfremmer.
3. Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til lokal behandling af - postoperative smertetilstande - smerter ved artritis - til lokale sårsmerter efter OP i form af en skyllevæske til intraoperativ anvendelse ved en åben eller artroskopisk eller endoskopisk operation, inklusive liposuction; ledsmerter; knoglesmerter efter osteotomi; - smerter ved frossen skulder - til lokale sårsmerter efter OP i form af en skyllevæske til intraoperativ anvendelse ved en åben eller artroskopisk eller endoskopisk operation inklusive liposuction; - lokal behandling af ledsmerter ved intraartikulær injektion ved artrose reumatoid artritis infektiøs artritis chondrocalcinose ligamentære skader menisklæsion bruskskader synovitis artrofibrose Morbus Sudeck nekrose i leddelene neuropatiske ledsmerter; lokal behandling af knoglesmerter efter knogleoperation ved påføring på knoglen, f.eks. efter bækkenkamosteotomi hallux valgus korrektion; behandling af knoglesmerter ved injektion i knoglen f.eks. ved femurhoved-nekrose i femurhovedet i hvirvellegemet ved osteochondrose lokal behandling af smerte ved ledstivhed, fortrinsvis artrofibrose eller frossen skulder; lokal behandling af muskelsmerter ved intramuskulær injektion, fortrinsvis ved fibersprængning, muskelømhed eller spastiske lidelser; lokal injektion i den smertende menisk ved meniskdegeneration eller meniskbristning; behandling af rygsmerter ved injektion i båndskiven ved båndskivedegeneration eller båndskivebristning; injektion omkring en smertende nerve, især ved trigeminusneuralgi, neurinom, Mortons neurom, fantomsmerte og cicatricielt neurom; behandling af tandsmerter ved lokal anvendelse intra/peridentalt ved: karies alle former for tandsmerte inden/ved/efter tandudtrækning inden/ved/efter tandimplantat lokal anvendelse ved parodontose lokal anvendelse ved blotlagte tandhalse; injektion i pleurahulen ved pleuritiske smerter; instillation i tarmen ved tarmsmerter, især Colitis ulcerosa, Crohns sygdom, og analfissur; kendetegnet ved, at A) midlet yderligere indeholder et calciumsalt; B) calciumionkoncentrationen er større end 2 mMol; C) midlet er opløst i en pufferopløsning med en pH-værdi højere end 7,6, fortrinsvis højere end 8,5; og D) midlet indeholder en permeationsfremmer.
4. Anvendelse ifølge krav 3, kendetegnet ved, at midlet ikke indeholder et lokalanæstetikum.
5. Anvendelse ifølge et af kravene 1 til 4, kendetegnet ved, at koncentrationen af RTX ligger mellem 100 nM og 10 μΜ.
6. Anvendelse ifølge krav 5, kendetegnet ved, at koncentrationen af RTX ligger mellem 500 nM og 1 μΜ.
7. Anvendelse ifølge et af kravene 1 til 6, kendetegnet ved, at midlet ikke indeholder alkohol, især ikke ethanol.
8. Anvendelse ifølge et af kravene 1 til 7, kendetegnet ved, at midlet yderligere indeholder et røntgenkontrastmiddel, fortrinsvis gadoliniumholdige, jodholdige eller bariumholdige stoffer.
9. Anvendelse ifølge et af kravene 1 til 8, kendetegnet ved, at midlet yderligere indeholder glycerin, fortrinsvis i en koncentration på 10 til 95 vægt-%.
10. Anvendelse ifølge et af kravene 1 eller 3 til 9, kendetegnet ved, at midlet yderligere indeholder et steroid.
11. Anvendelse ifølge et af kravene 1 eller 3 til 10, kendetegnet ved, at midlet yderligere indeholder en vasokonstriktor, fortrinsvis adrenalin, noradrenalin, phenylephrin eller ornipressin.
12. Anvendelse ifølge et af kravene 1 til 11, kendetegnet ved, at midlet er opløst i et biokompatibelt opløsningsmiddel, fortrinsvis i glycerin, iofendylat eller propylenglykol.
13. Anvendelse ifølge et af kravene 1 til 12, kendetegnet ved, at midlet anvendes til denervering eller neurolyse i degenerativt angrebne led.
14. Anvendelse ifølge et af kravene 1 til 13, kendetegnet ved, at midlet er opløst i en bærervæske (carrier), en farmakologisk acceptabel vehikel, især fra gruppen natriumchloridinjektionsopløsning, Ringers injektionsopløsning, isoto-nisk dextrose, steril vand-dextroseopløsning, lakteret Ringers injektionsopløsning, destilleret vand eller blandinger deraf, til lokal injektion.
15. Anvendelse ifølge et af kravene 1 til 6 eller 8 til 14, kendetegnet ved, at permeationsfremmeren er udvalgt blandt følgende gruppe af stoffer: dimethylsulfoxid, ethoxyethylendiglycol, ethanol, phosphatidylcholin, propylen-gylcol dipelargonat (DPPG) eller glycoliserede ethoxylerede glycerider.
16. Anvendelse ifølge et af kravene 1 til 15, kendetegnet ved, at midlet yderligere indeholder et stof, der muliggør en forsinket eller prolongeret frigivelse af RTX.
17. Anvendelse ifølge krav 16, kendetegnet ved, at stoffet er glucosamino-glycan eller hyaluronsyre.
18. Anvendelse ifølge et af kravene 1 til 17, kendetegnet ved, at midlet indeholder en permeationsfremmer.
19. Anvendelse ifølge et af kravene 1 til 18, kendetegnet ved, at kalciumion-koncentrationen er større end 4 mMol.
20. Anvendelse ifølge krav 18 eller 19, kendetegnet ved, at de i opløsningsmediet opløste salte og ioner er koncentreret højere end fysiologisk normalt (f.eks. i Ringer lactatopløsning).
21. Middel til anvendelse ved behandling af smerter, kendetegnet ved, at resiniferatoxin (RTX) er opløst i et egnet biokompatibelt opløsningsmiddel, og et væskevolumen på 0,1 til 150 ml deraf fortrinsvis a) injiceres lokalt i patientens smerteangrebne vævsstruktur; eller b) dryppes lokalt på operationssåret; eller c) injiceres lokalt i det intrakapsulære område, eller d) injiceres lokalt i synoviallommen af et af smerter ramt led, kendetegnet ved, at A) midlet yderligere indeholder et calciumsalt; B) calciumionkoncentrationen er større end 2 mMol; C) midlet er opløst i en pufferopløsning med en pH-værdi højere end 7,6, fortrinsvis højere end 8,5; og D) der anvendes resiniferatoxin (RTX) i en sådan koncentration, at der optræder en neurolyse.
22. Middel til anvendelse ifølge krav 21, kendetegnet ved, at de nociceptive nervefibre gøres smerteufølsomme ved hjælp af resiniferatoxin (RTX) i mindst 14 dage, fortrinsvis mindst 8 uger.
23. Middel til anvendelse ifølge krav 21 eller 22, kendetegnet ved, at koncentrationen af RTX ligger mellem cirka 10 nanoMolar (nM) til 100 mikroMolar (μΜ).
24. Middel til anvendelse ifølge et af kravene 21 - 23, kendetegnet ved, at det anvendes til følgende indikationer: - til lokale sårsmerter efter OP i form af en skyllevæske til intraoperativ anvendelse ved en åben eller artroskopisk eller endoskopisk operation samt liposuction; - lokal behandling af ledsmerter ved intraartikulær injektion ved artrose reumatoid artritis infektiøs artritis chondrocalcinose ligamentære skader menisklæsion bruskskader synovitis artrofibrose Morbus Sudeck nekrose i leddelene neuropatiske ledsmerter; lokal behandling af knoglesmerter efter knogleoperation ved påføring på knoglen, f.eks. efter bækkenkamosteotomi eller hallux valgus korrektion; behandling af knoglesmerter ved injektion i knoglen, f.eks. ved femurhoved-nekrose i femurhovedet, i hvirvellegemet ved osteochondrose, lokal behandling af smerter ved ledstivhed, fortrinsvis ved artrofibrose eller frossen skulder; lokal behandling af muskelsmerter ved intramuskulær injektion, fortrinsvis ved fibersprængning, muskelømhed eller spastiske lidelser; lokal injektion i den smertende menisk ved meniskdegeneration eller meniskbristning; behandling af rygsmerter ved injektion i båndskiven ved båndskivedegeneration eller båndskivebristning; injektion omkring en smertende nerve, fortrinsvis ved trigeminusneuralgi, neurinom, Mortons neurom, fantomsmerte eller cicatricielt neurom; behandling af tandsmerter ved lokal anvendelse intra/peridentalt ved: karies alle former for tandsmerte inden/ved/efter tandudtrækning inden/ved/efter tandimplantat lokal anvendelse ved parodontose lokal anvendelse ved blotlagte tandhalse; injektion i pleurahulen ved pleuritiske smerter; instillation i tarmen ved tarmsmerter, især ved Colitis ulcerosa, Crohns sygdom eller analfissur.
25. Middel til anvendelse ifølge et af kravene 21 til 24, kendetegnet ved, at midlet indsprøjtes i et synovialt hulrum, der ikke er foret med urothel.
26. Resiniferatoxin til anvendelse i et middel til behandling af artrose artritis, især reumatoid artritis og infektiøs artritis chondrocalcinose ligamentære skader menisklæsion bruskskader synovitis artrofibrose Morbus Sudeck nekrose i leddelene neuropatiske ledsmerter behandling af knoglesmerter efter knogleoperation ved påføring på knoglen, f.eks. efter bækkenkamosteotomi hallux valgus korrektion behandling af knoglesmerter ved injektion i knoglen f.eks. ved femurhovednekrose i femurhovedet i hvirvellegemet ved osteochondrose behandling af smerte ved ledstivhed, især artrofibrose frossen skulder behandling af muskelsmerter ved intramuskulær injektion, f.eks. ved fibersprængning muskelømhed spastiske lidelser injektion i den smertende menisk ved meniskdegeneration eller meniskbristning, behandling af rygsmerter ved injektion i båndskiven ved båndskivedegeneration eller båndskivebristning; injektion omkring en smertende nerve, f.eks. ved trigeminusneuralgi neurinom Mortons neurom fantomsmerte cicatricielt neurom; behandling af tandsmerter intra/peridentalt ved: karies alle former for tandsmerte inden/ved/efter tandudtrækning inden/ved/efter tandimplantat anvendelse ved parodontose anvendelse ved blotlagte tandhalse; injektion i pleurahulen ved pleuritiske smerter; instillation i tarmen ved tarmsmerter, især Colitis ulcerosa, Crohns sygdom, analfissur, hæmorider; ledsmerter; knoglesmerter efter osteotomie; frossen skulder; tendonitis; myalgi; smerter ved bløddelstumorer knoglesmerter eller knogleledssmerter, kendetegnet ved, at A) midlet yderligere indeholder et calciumsalt; B) calciumionkoncentrationen er større end 2 mMol; C) midlet er opløst i en pufferopløsning med en pH-værdi højere end 7,6, fortrinsvis højere end 8,5; og D) midlet ikke indeholder et lokalanæstetikum.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CH2004/000756 WO2006069451A1 (de) | 2004-12-28 | 2004-12-28 | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1838301T3 true DK1838301T3 (da) | 2015-04-27 |
Family
ID=34959549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04802396.4T DK1838301T3 (da) | 2004-12-28 | 2004-12-28 | Anvendelse af resiniferatoxin (RTX) til fremstilling af et middel til behandling af smerter |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080139641A1 (da) |
| EP (1) | EP1838301B1 (da) |
| JP (1) | JP5775246B2 (da) |
| CA (1) | CA2594202C (da) |
| DK (1) | DK1838301T3 (da) |
| ES (1) | ES2533256T3 (da) |
| PL (1) | PL1838301T3 (da) |
| WO (1) | WO2006069451A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063842A2 (en) | 2006-11-02 | 2008-05-29 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
| US8697155B2 (en) * | 2008-07-22 | 2014-04-15 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| JP6195561B2 (ja) | 2011-06-10 | 2017-09-13 | クイーン マリー ユニバーシティ オブ ロンドン | 外傷出血および関連症状の治療における使用のための、アルテミシニンおよびその誘導体 |
| JP2015523401A (ja) * | 2012-08-03 | 2015-08-13 | メステックス・アー・ゲー | レシニフェラトキシン溶液 |
| US9603831B2 (en) | 2012-12-12 | 2017-03-28 | Queen Mary & Westfield College, University Of London | Artemisinin and its derivatives for use in the treatment of kidney disease |
| US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
| KR102657458B1 (ko) | 2016-11-02 | 2024-04-12 | 센트렉시온 테라퓨틱스 코포레이션 | 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도 |
| EP3641746B1 (en) * | 2017-06-19 | 2024-11-20 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| WO2019018769A1 (en) | 2017-07-20 | 2019-01-24 | Centrexion Therapeutics Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE |
| KR20200051771A (ko) * | 2017-09-11 | 2020-05-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | 레시니페라톡신 제형 |
| CN113490745A (zh) * | 2018-12-21 | 2021-10-08 | 索伦托药业有限公司 | 神经周施用树脂毒素治疗适应不良性疼痛 |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| EP3914595A4 (en) * | 2019-01-22 | 2022-11-09 | Sorrento Therapeutics, Inc. | METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN |
| CN110123833A (zh) * | 2019-05-31 | 2019-08-16 | 龚啸元 | 一种关节镜手术用灌流液及其制备方法 |
| PL4135652T3 (pl) * | 2020-04-15 | 2025-03-10 | Grünenthal GmbH | Kompozycje rezyniferatoksyny |
| US20250228815A1 (en) | 2024-01-15 | 2025-07-17 | Gruenenthal Gmbh | Lyophilized resiniferatoxin |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3104085A (en) | 1960-07-18 | 1963-09-17 | Ind Paper Log Inc | Compressed fibrous articles |
| US4939149A (en) | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
| US4997853A (en) | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
| AU5744490A (en) * | 1989-05-15 | 1990-12-18 | Afferon Corporation | Composition and method for neural desensitization |
| ATE219674T1 (de) | 1997-03-13 | 2002-07-15 | James N Campbell | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
| GB9711962D0 (en) | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| JP2004511803A (ja) * | 2000-10-16 | 2004-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | バニロイド受容体についての改良リガンド結合アッセイ |
| JP2004521112A (ja) * | 2001-01-24 | 2004-07-15 | メステックス アクチエンゲゼルシャフト | 関節痛治療薬を製造することへの神経毒性物質の使用 |
| CA2442049C (en) | 2001-03-22 | 2010-06-01 | Michael J. Iadarola | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
| US20030104085A1 (en) * | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| PT1605956E (pt) | 2002-12-18 | 2016-03-09 | Centrexion Therapeutics Corp | Administração de capsaicinóides para o tratamento da osteoartrite |
| DE502004011941D1 (de) * | 2004-12-22 | 2011-01-05 | Mestex Ag | Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels |
-
2004
- 2004-12-28 ES ES04802396.4T patent/ES2533256T3/es not_active Expired - Lifetime
- 2004-12-28 JP JP2007548653A patent/JP5775246B2/ja not_active Expired - Lifetime
- 2004-12-28 EP EP04802396.4A patent/EP1838301B1/de not_active Expired - Lifetime
- 2004-12-28 WO PCT/CH2004/000756 patent/WO2006069451A1/de not_active Ceased
- 2004-12-28 PL PL04802396T patent/PL1838301T3/pl unknown
- 2004-12-28 DK DK04802396.4T patent/DK1838301T3/da active
- 2004-12-28 US US11/722,779 patent/US20080139641A1/en not_active Abandoned
- 2004-12-28 CA CA 2594202 patent/CA2594202C/en not_active Expired - Lifetime
-
2010
- 2010-04-07 US US12/755,994 patent/US9044452B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5775246B2 (ja) | 2015-09-09 |
| CA2594202A1 (en) | 2006-07-06 |
| EP1838301B1 (de) | 2015-01-28 |
| PL1838301T3 (pl) | 2015-08-31 |
| US9044452B2 (en) | 2015-06-02 |
| ES2533256T3 (es) | 2015-04-08 |
| WO2006069451A1 (de) | 2006-07-06 |
| EP1838301A1 (de) | 2007-10-03 |
| CA2594202C (en) | 2013-12-03 |
| JP2008525504A (ja) | 2008-07-17 |
| US20100196281A1 (en) | 2010-08-05 |
| US20080139641A1 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9044452B2 (en) | Use of resiniferatoxin (RTX) for producing an agent for treating joint pains and method for applying said agent | |
| CA2592086C (en) | Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller | |
| US8703741B2 (en) | Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan | |
| JP2004521112A (ja) | 関節痛治療薬を製造することへの神経毒性物質の使用 | |
| JP2008525504A5 (da) | ||
| JP2008533140A (ja) | 術後鎮痛剤の低減 | |
| US7964644B2 (en) | Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means | |
| RU2426564C1 (ru) | Способ лечения асептического некроза головки бедренной кости | |
| RU2299733C1 (ru) | Способ лечения дегенеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических спаечных процессов | |
| RU2845795C1 (ru) | Способ лечения ранних стадий остеохондральных поражений нижних конечностей | |
| RU2368339C1 (ru) | Способ послеоперационного лечения больных с открытой травмой голеностопного сустава | |
| RU2701363C1 (ru) | Способ послеоперационной пролонгированной анестезии при эндопротезировании тазобедренного сустава | |
| RU2027433C1 (ru) | Способ лечения мицетомы стоп | |
| RU2289407C2 (ru) | Способ купирования дыхательной и сердечно-сосудистой недостаточности при лечении пневмонии |